ClinicalTrials.gg
CompletedNCT05473195BETOUpdated Aug 21, 2025

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098

A Phase 2 interventional study of BVL-GSK098 9mg and Ethionamide 250mg in Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB), sponsored by TASK Applied Science. Completed at 1 site in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by TASK Applied Science · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Tuberculosis, Pulmonary with a site in South Africa — 10 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis, Pulmonary · South Africa.

Enrollment
40th of 67
105 · median 122
Started
2022
with 8 others
Phase 2
49 of 78
8 open now
Registered
60th of 78
by date
Lead sponsor
6 of 78
TASK Applied Science

Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, this one is the 40th largest by enrollment of the 67 interventional ones that give a count, is one of 9 that started in 2022, is one of 49 in phase 2, and was the 60th registered.

Tuberculosis, Pulmonary

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

10 of the 78 studies in Tuberculosis, Pulmonary with a site in South Africa are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Tuberculosis, Pulmonary with a site in South Africa, or all of them as a file.
02

Study summary

To evaluate the 7-day early bactericidal activity (EBA), pharmacokinetics (PK), safety and tolerability of ethionamide (Eto) with or without BVL-GSK098 in participants with rifampicin- and isoniazid-susceptible pulmonary TB.

Read the detailed description

A single-centre, open-label, clinical trial in two stages. All treatments will be administered orally (PO) on days 1-7.

Stage 1 will recruit 15 participants into arm 1 who will receive Eto and a low dose BVL-GSK098 combination (bEto), including 3 participants from the control arm (arm 2). Participants will be randomized 5:1. This will be followed by a recruitment pause and an interim analysis to evaluate safety of the combination.

Stage 1:

Arm Regimen Participants

  1. BVL-GSK098 9 mg once daily (OD) plus ethionamide 250 mg OD (b9Eto250) 15
  2. Isoniazid 300 mg po OD (INH) 3 * BVL-GSK098 9 mg will be given 12-hourly on Day one (loading dose), then once daily on Day 2-7.

An interim safety analysis will be performed after all Stage 1 participants complete the end of treatment visit (Day 8). If the b9Eto250 arm meets the predefined safety criteria (Section 9), the study will proceed to Stage 2. Recruitment will then continue with the remaining arms randomized in a 4:5:5:5:5:5 ratio.

Stage 2:

Arm Regimen Participants 2 Isoniazid 300 mg po OD (INH) 12 3 BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125) 15 4 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) 15 5 BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500) 15 6 Ethionamide 250 mg po OD (Eto250) 15 7 Ethionamide 750 mg po given in a single or divided dose daily (Eto750) 15

* BVL-GSK098 27 mg will be given 12-hourly on Day one (loading dose), then once daily on Day 2-7. Ethionamide 750 mg given in divided doses Day 1-3, and OD Day 4-7.

Participants on INH will serve as control for the EBA quantitative mycobacteriology. The study will not be blinded but the mycobacteriology laboratory staff performing the endpoint assays will remain blinded until analysis of the EBA results.

03

Conditions studied

  • Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participants are required to meet all the following criteria in order to be randomized.

  1. Provide written, prior to all trial-related procedures.
  2. Male or female, aged between 18 and 65 years, inclusive.
  3. Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.
  4. Newly diagnosed and untreated pulmonary TB.
  5. Rifampicin- and isoniazid-susceptible pulmonary TB as determined by molecular testing (GeneXpert XDR or Genotype MTBDRplus for INH).
  6. A chest X-ray taken during the screening period or up to 2 weeks before screening which, in the opinion of the investigator, is consistent with TB.
  7. GeneXpert positive with a quantitative readout of medium or high.
  8. Ability to produce an adequate volume of sputum as estimated from an overnight sputum collection sample (estimated 10 ml or more).
  9. Be of non- or using effective methods of .
  10. For WOCBP, injectable or other contraceptive methods (per Appendix 1) need to be given prior to or during screening, and at least 2 days prior to first dose of IP.

Exclusion criteria

Exclusion Criteria:

  • Participants will be excluded from participation if they fulfil any of the following criteria.

Medical History

  1. Evidence of conditions or findings, other than TB, that might compromise safety or the interpretation of trial endpoints, per discretion of the investigator.
  2. History of epilepsy, seizures or other neuropsychiatric disorders that might compromise safety or the interpretation of trial endpoints, per discretion of the investigator
  3. History of hypothyroidism
  4. of >450 ms at baseline
  5. Clinically significant evidence of extrathoracic TB, as judged by the investigator.
  6. History of allergy to any of the trial IP as confirmed by the clinical judgement of the investigator.
  7. Alcohol or drug abuse, that in the opinion of the investigator, is sufficient to compromise the safety or cooperation of the participant.
  8. positive AND:

    1. CD4 \< 250cells/mm3
    2. OR, on ART in stage 1 only. Participants established on ART (2 NRTIs and dolutegravir) for more than 30 days at start of screening are eligible for participation in stage 2.

    NOTE: ART permitted in Stage 2 is limited to the following in line with local guidelines for ART:

    • NRTIs selected from: Emtricitabine, Lamivudine, Tenofovir
    • PLUS Dolutegravir

    As the drug-drug interaction potential of ART has not been fully investigated with the IP, NNRTIs (efavirenz, nevirapine) and other protease inhibitors will not be permitted in this study.

  9. Female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of trial participation. Male participant planning to conceive a child for at least 90 days, after the last dose of study intervention in the trial.

    Treatment History

  10. Participation in other clinical studies with agents within 8 weeks prior to screening.
  11. Treatment received for this episode of TB with any drug active against M.tb (including but not limited to isoniazid, ethambutol, amikacin, cycloserine, fluoroquinolones, rifabutin, rifampicin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, pyrazinamide, thioacetazone, capreomycin, thioamides).
  12. Treatment with medications such as TNF-alpha inhibitors within 2 weeks prior to screening, or systemic for more than 7 days within 2 weeks prior to screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Arm 1

    BVL-GSK098 9 mg once daily (OD) plus ethionamide 250 mg OD (b9Eto250)

    Drug: BVL-GSK098 9mg · Drug: Ethionamide 250mg

  • Active comparator
    Arm 2

    Isoniazid 300 mg po OD (INH)

    Drug: Isoniazid 300 MG

  • Experimental
    Arm 3

    BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125)

    Drug: BVL-GSK098 9mg · Drug: Ethionamide 250mg

  • Experimental
    Arm 4

    BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250)

    Drug: BVL-GSK098 9mg · Drug: Ethionamide 250 mg

  • Experimental
    Arm 5

    BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)

    Drug: Ethionamide 250mg

  • Experimental
    Arm 6

    Ethionamide 250 mg po OD (Eto250)

    Drug: Ethionamide 250 mg

  • Experimental
    Arm 7

    Ethionamide 750 mg po given in a single or divided dose daily (Eto750)

    Drug: Ethionamide 250mg

Interventions

  • DrugAlpibectirStudies of AlpibectirAlpibectir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)

    Also known as: Ethionamide 125 and 250mg

  • DrugEthionamide 250mg

    Ethionamide 250 mg po OD (Eto250)

  • DrugEthionamide 250 mg

    Ethionamide 750 mg po given in a single or divided dose (Eto750)

    Also known as: Ethionamide 250mg

  • DrugIsoniazidStudies of IsoniazidIsoniazid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Isoniazid 300 mg po OD (INH)

06

What researchers measure

Primary outcomes

  1. EBA CFU

    The EBA CFU(0-7) as determined by the predicted rate of change in log10CFU per ml sputum over the period day 0 to day 7 will be described using linear, bi-linear or non-linear functions using nonlinear mixed effects modelling as dictated by the data of log10CFU over time and relation to drug exposure. Predicted estimate of rates of change including uncertainties for the potential differences in treatment effects between the groups will be given and graphically illustrated.

    Time frame: 7 days

Secondary outcomes

  1. EBA TTP

    The EBA TTP(0-7) as determined by the predicted rate of change in TTP over the period day 0 to day 7 will be described using linear, bi-linear or non-linear functions using nonlinear mixed effects modelling of TTP over time and relation to drug exposure.

    Time frame: 7 days

Other outcomes

  1. Adverse events

    The incidence of the following events will be summarized by treatment group: * Incidence of treatment-emergent adverse events (TEAEs); * Incidence of TEAEs by Severity; * Incidence of drug related TEAEs; * Incidence of Serious TEAEs; * Incidence of TEAEs leading to early withdrawal; * Incidence of TEAEs leading to death. Descriptive summary statistics will be presented for other safety variables: laboratory parameters, physical examination, vital signs, concomitant medication.

    Time frame: 7 days

07

Study locations

1 site
  • TASK Clinical Research Centre
    Cape Town, Western Cape 7530, South Africa
08

References and documents

Individual participant data

Plan to share: Yes — Plan not yet available

Supporting information: Study protocol

Time frame: Immediately after publication.

Access criteria: Not available yet

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Apr 2024, 16 months.

Of 33 non-industry phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 49. This study's 16 months is below that.

Counting every sponsor, half of 43 studies reached it within 30 months; a quarter within 21 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2022
First posted
Jul 25, 2022
StartActual
Dec 6, 2022
Primary completionActual
Apr 16, 2024
CompletionActual
Apr 16, 2024
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05473195
Lead sponsor
TASK Applied Science
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 25, 2022
Start date
Dec 6, 2022
Primary completion
Apr 16, 2024
Completion
Apr 16, 2024
Last update
Aug 21, 2025

Study contacts

Reinard McPherson, MBChB
principal investigator · TASK

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpibectir

Start the discussion